Nxera Pharma Co Eulerpool News

Nxera Pharma Co Eulerpool News

Nxera Pharma Co Stock News

Nxera Pharma Co is being monitored by journalists and investors worldwide. We gather the latest Nxera Pharma Co news here.

• October 1 ·

  Yahoo
  Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
• October 1 ·

  Yahoo
  Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
• September 24 ·

  Yahoo
  Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
• September 13 ·

  Yahoo
  Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
• September 11 ·

  Yahoo
  Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
• September 2 ·

  Yahoo
  Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
• August 28 ·

  Yahoo
  Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
• August 9 ·

  Yahoo
  Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
• July 9 ·

  Yahoo
  Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
• July 9 ·

  SeekingAlpha
  Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth